Prevention of Post-transplant Cardiovascular Disease – Report and Recommendations of an Ad Hoc Group

Kidney, heart, liver, and, to a lesser extent, pancreas and lung transplants have become routine treatments for end‐stage organ failure. The short‐term success rate is high. Graft loss from allograft rejection, the traditional enemy of transplantation, has been greatly reduced. These improved results have yielded patient survival rates at 1 and 3 years that exceed 90%.